Ricki Carroll, MD, MBE

Financial relationships

  • Type of financial relationship:
    Other
    Ineligible company:
    Biomarin
    Topic:
    PI for achondroplasia trial
    Date added:
    09/20/2023
    Date updated:
    10/26/2026
  • Type of financial relationship:
    Other
    Ineligible company:
    Ascendis
    Topic:
    PI for achondroplasia trial
    Date added:
    09/20/2023
    Date updated:
    10/26/2026
  • Type of financial relationship:
    Consultant
    Ineligible company:
    BridgeBio
    Topic:
    co-I for achondroplasia trial, medical advisory board
    Date added:
    09/20/2023
    Date updated:
    10/26/2026
  • Type of financial relationship:
    Other
    Ineligible company:
    Medlife
    Topic:
    co-I for RCDP natural history trial
    Date added:
    09/20/2023
    Date updated:
    10/26/2026
  • Type of financial relationship:
    Consultant
    Ineligible company:
    Actio
    Topic:
    Metatropic dysplasia
    Date added:
    09/20/2023
    Date updated:
    10/26/2026
    Relationship end date:
    06/01/2026
  • Type of financial relationship:
    Consultant
    Ineligible company:
    Guidepoint
    Topic:
    Skeletal dysplasia pharmaceuticals landscape
    Date added:
    09/20/2023
    Date updated:
    10/26/2026
  • Type of financial relationship:
    Other
    Ineligible company:
    Ultragenyx
    Topic:
    PI for OI trial
    Date added:
    09/20/2023
    Date updated:
    10/26/2026
  • Type of financial relationship:
    Consultant
    Ineligible company:
    BioMarin
    Topic:
    Use of voxzogo in FGFR3-opathies
    Date added:
    09/20/2024
    Date updated:
    10/26/2026
  • Type of financial relationship:
    Other
    Ineligible company:
    Tyra
    Topic:
    PI for achondroplasia clinical trial
    Date added:
    09/04/2025
    Date updated:
    10/26/2026
  • Type of financial relationship:
    Consultant
    Ineligible company:
    Ascendis
    Topic:
    Use of transcon-CNP in FGFR3-opathies
    Date added:
    09/04/2025
    Date updated:
    10/26/2026
Return to From Prenatal Diagnosis to Delivery and Beyond: Optimizing Outcomes for Rare Genetic Musculoskeletal Disorders